Planning to attend the BioWednesday Summer Social on 14 August 2019? Do you fancy winning one of our wise owls? By registering for the event you are automatically entered into the competiton to win one of the below owls!
Register here. Remember, One Nucleus members can attend all our BioWednesday events for free.
Terms and ConditionsThree owls to give away at the event by a random hat draw.Each person registered will be entered into the competition. You can win even if you're not in attendance (but you should still definitely attend!)
**Please note that the eyes are pins (with backings) so…
• Career that spans biotech and pharma including at Astex Pharmaceuticals and GSK
• Has led discovery of over 10 drugs taken into clinical development, including the two recent drugs from the Astex stable that have received marketing approval
• Will grow in-house drug development team to harness power of AI and take rare disease treatments from prediction through to the clinical stage
Cambridge, UK – 11 July 2019 – Healx, the Cambridge (UK) technology company developing breakthrough treatments for rare diseases, today announces the appointment of Dr Neil Thompson, PhD, as Chief Scientific…
Westbury, NY – July 10, 2019 – BioIVT, a leading provider of research models and services for drug and diagnostic development, today announced that it is hosting a webinar that will present the latest in vitro research methods and International Transporter Consortium (ITC) guidance for assessing bile salt export pump (BSEP) inhibition to reduce and manage the risk of drug-induced liver injury (DILI) during drug development.
BSEP, a canalicular membrane transport protein, is responsible for bile acid efflux from hepatocytes in the liver and is of critical importance for normal bile flow and…
Invest Newcastle has welcomed a senior Cuban life science business delegation to the region for a two-day visit. They used this opportunity to show off the city’s life science strengths and world-leading universities.
After meeting Matt Bratton, Senior Investment Manager from Invest Newcastle at a conference in London, businesses were keen to find out more about the UK’s life science sector as well as build academic and research partnerships. Working closely with the Department of International Trade Havana, Invest Newcastle hosted a 2-day programme as part of a UK trip to Edinburgh,…
AMSBIO announce new, best-in-class CAR-T cells, engineered CAR-T target cells, PBMC, cell media and activation beads in response to the rapid growth in research on the therapeutic uses of CAR-T cells.All CAR-T cell products from AMSBIO are T cells produced from either a group of donors or from individual donor transduced with CAR (Chimeric antigen receptor) - lentivirus.These CAR-T cells can target different tumor antigens such CD19, CD133, Her-2, EGFR, VEGFR-2 or mesothelin that are highly over-expressed in tumors. These CAR-T cells can express inducible caspase-9 or other suicide…
SOMERSET, N.J. – July 9, 2019 — Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies, and development and manufacturing solutions for drugs, biologics, gene therapies, and consumer health products, today announced that it has significantly expanded the capacity of its global spray drying operations through an agreement with Sanofi Active Ingredient Solutions, an industrial platform of Sanofi, under which Sanofi will provide Catalent with access to spray drying manufacturing services for Catalent’s customers at Sanofi’s Haverhill, U.K. facility.
This…
Cambridge, UK, 4th July, 2019: We are delighted to announce Sunil Shah, CEO, o2h Ventures, has won the prestigious UKBAA Angel Investor of the Year Award for his active participation in backing high growth potential startups and early-stage businesses in the UK. Sunil’s contribution has been instrumental in the growth of biotech in UK. He has been investing into the biotech therapeutics sector since many years – a sector from which traditionally many angel investors have stayed away. Over the years, Sunil has championed EIS Angel investing and biotech therapeutics to generate investment into…
Arecor Limited (“Arecor” or “the Company”), the specialty pharmaceutical company leveraging its innovative and proprietary formulation technology to develop superior treatments for a range of disease areas, including diabetes, today announces that it has signed a further collaboration with a major global pharmaceutical company.
Under this new agreement, Arecor will use its proprietary formulation technology platform Arestat™ to develop a differentiated, thermostable liquid formulation of one of the global pharmaceutical company’s key proprietary products. The new formulation will be stored…
On Thursday 4 July Dr. Fiona Marshall, Global Head of Neuroscience Discovery, MSD visited Newcastle to mark the official launch of The Biosphere.
Located at Newcastle Helix, The Biosphere is a specialist lab facility tailored to commercialisation of life sciences. It provides biology and chemistry laboratories and high-quality office space.
Dr. Fiona Marshall was joined by Cllr Ged Bell, Cabinet Member for Employment and Investment and Pat Ritchie, Chief Executive, Newcastle City Council who used this opportunity to bring the sector together and thank everyone who has…
Cambridge, UK, 08 July 2019: PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has entered into a structural biology focussed collaboration with the Centre for Chemical Biology and Therapeutics (CCBT), Bangalore, India. CCBT at the Institute for Stem Cell Science and Regenerative Medicine (inStem) is funded by the Department of Biotechnology, Government of India,. The aim of the collaboration is the structural visualisation of novel druggable sites across multiple targets, to rapidly advance new therapies.
PhoreMost…